Catalyst Pharmaceutical Partners, Inc. (CPRX) said Thursday that it has priced an underwritten offering of 6 million units, with each unit consisting of one share of its common stock and a warrant to purchase up to one share of its common stock, at a public offering price of $0.80 per unit.
Catalyst expects to receive net proceeds of about $4.0 million, not including any cash proceeds from a future exercise of the warrants, after deducting the underwriting discount and estimated offering expenses. The warrants will have a 5-year term and an exercise price equal to $1.04 per share.
The offering is expected to close on May 30.
The proceeds of this offering will be used: to fund the activities necessary to support the submission of an NDA for CPP-109 for FDA approval and to begin to prepare for the commercial launch of CPP-109, assuming that the data from the currently ongoing Phase II(b) trial are compelling and the FDA accepts an NDA submitted by Catalyst for CPP-109 based on the data from the Phase II(b) trial; to manufacture sufficient CPP-115 for use in one or more future safety and/or proof-of-concept studies of CPP-115; and for general corporate purposes.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.